Related Experiment Videos
Hydroxyurea therapy for pediatric patients with hemoglobin SC disease
M K Miller1, S A Zimmerman, W H Schultz
1Department of Pediatrics, Duke University Medical Center, Durham, North Carolina 27710, USA.
Journal of Pediatric Hematology/Oncology
|July 24, 2001
Summary
Hydroxyurea (HU) therapy shows significant laboratory benefits, including increased fetal hemoglobin, in pediatric patients with severe sickle cell hemoglobin SC (HbSC) disease. Clinical improvements were observed, warranting further investigation in larger trials.
Area of Science:
- Hematology
- Pediatric Medicine
- Pharmacology
Background:
- Sickle cell hemoglobin SC (HbSC) disease affects numerous pediatric patients.
- The efficacy of hydroxyurea (HU) in HbSC disease remains largely unestablished.
- Previous studies in HbSS disease indicate HU's therapeutic potential.
Purpose of the Study:
- To assess the laboratory and clinical responses of pediatric patients with severe HbSC disease to HU therapy.
- To evaluate the safety and tolerability of HU in this population.
Main Methods:
- Retrospective case series of six pediatric patients with severe HbSC disease.
- Patients received oral HU therapy, with dosage titrated to the maximum tolerated level.
- Laboratory parameters and clinical outcomes were monitored regularly.
Main Results:
- Significant increases in mean corpuscular volume, percentage of fetal hemoglobin, and percentage of F cells were observed.
- A significant decrease in neutrophils was noted.
- Patients experienced mild and reversible toxicity, with two cases reported.
Conclusions:
- Hydroxyurea therapy demonstrated striking laboratory improvements in pediatric HbSC patients, comparable to those in HbSS disease.
- All patients exhibited clinical improvement during the treatment period.
- HU therapy is beneficial for pediatric patients with severe HbSC disease, supporting the need for larger clinical trials.